Theriva Biologics Inc.
$ 0.22
-1.78%
07 Aug - close price
- Market Cap 10,133,100 USD
- Current Price $ 0.22
- High / Low $ 0.23 / 0.22
- Stock P/E N/A
- Book Value 0.34
- EPS -0.58
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -1.39 %
- 52 Week High 0.86
- 52 Week Low 0.16
About
Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$2.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-12 | 2025-11-12 | 2025-08-11 | 2025-05-14 | 2025-03-06 | 2024-11-12 | 2024-08-13 | 2024-05-07 | 2024-03-25 | 2023-11-13 | 2023-08-08 |
| Reported EPS | -0.05 | -0.0982 | -0.45 | -1.93 | -1.55 | -11.49 | -6.81 | -10.75 | -7.5 | -0.34 | -4.75 | -8.5 |
| Estimated EPS | -0.05 | -0.37 | -0.38 | -0.47 | -1.56 | -7.22 | -5.25 | -4.75 | -8.5 | -0.41 | -8.5 | -8.5 |
| Surprise | 0 | 0.2718 | -0.07 | -1.46 | 0.01 | -4.27 | -1.56 | -6 | 1 | 0.07 | 3.75 | 0 |
| Surprise Percentage | 0% | 73.4595% | -18.4211% | -310.6383% | 0.641% | -59.1413% | -29.7143% | -126.3158% | 11.7647% | 17.0732% | 44.1176% | 0% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TOVX
2026-08-07 17:39:39
This article provides an earnings forecast for Theriva Biologics Inc (TOVX), highlighting its current earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $7.00 for TOVX, with two analysts recommending a "Buy" rating. The report also includes past and projected EPS figures for the company.
2026-08-07 09:39:39
This article announces that Theriva Biologics Inc. filed a Form 8K on August 6th, as reported by Investing.com. The content is brief and primarily serves as a notification of the filing, without providing details about the 8K's contents. It includes a stock symbol (TOVX) and a slight price decrease for the company.
2026-08-07 09:39:39
Theriva™ Biologics has announced the dosing of the first patient in its VIRAGE2 Phase 2a clinical trial. This study will evaluate more frequent dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients, building on positive data from the VIRAGE Phase 2b study. The goal is to refine the VCN-01 dosing regimen for a future pivotal Phase 3 clinical trial, with initial data expected by Q3 2027.
2026-08-06 12:40:44
Theriva Biologics has initiated its VIRAGE2 Phase 2a clinical trial, dosing the first patient with VCN-01 for metastatic pancreatic ductal adenocarcinoma (PDAC). This proof-of-concept study aims to evaluate more frequent dosing of VCN-01 in combination with standard chemotherapy, building on previous positive results. The trial's findings are expected by Q3 2027 and will inform the design of a potential pivotal Phase 3 trial.
2026-08-06 12:40:44
This article reports on the filing of a Form 8K by Theriva Biologics Inc. on August 6. It includes general stock market information and financial data, but the core content is a brief announcement about the Form 8K filing.
2026-08-06 11:40:44
Theriva Biologics has dosed the first patient in its VIRAGE2 Phase 2a clinical trial, evaluating more frequent dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic pancreatic ductal adenocarcinoma patients. This 6-patient, single-arm, open-label study aims to assess the tolerability and pharmacodynamics of at least three VCN-01 doses, given approximately two months apart, in combination with standard chemotherapy. The results will inform the design of a potential future pivotal Phase 3 trial, building on previous observations of improved survival with two VCN-01 doses.
